Congenital adrenal hyperplasia is one of the most frequently inherited diseases. It is characterized by a severe decline in cortisol secretion, which results in a compensatory increase in ACTH and consequent adrenal growth (hyperplasia). Here we describe the first case of 11␤-hydroxylase deficiency that is caused by an unequal cross-over of the genes encoding aldosterone synthase (CYP11B2) and 11␤-hydroxylase (CYP11B1). CYP11B1 and CYP11B2 are located on chromosome 8q24 approximately 45 kb apart from each other. The investigated genetic recombination deleted the normal alleles of the two genes and created a chimeric fusion gene, which consists of the promotor and exons 1 through 4 of the aldosterone synthase gene plus intron 4 through exon 9 of the 11␤-hydroxylase gene. This recombination event subordinates any remaining 11␤-hydroxylase activity of the chimeric enzyme to the control mechanisms of CYP11B2, the expression of which is mainly regulated by angiotensin II and K ؉ . Normally the 11␤-hydroxylase activity is controlled by ACTH. The existence of the CYP11B2/CYP11B1 chimera was discovered by means of a PCR method and was confirmed with a Southern M ORE THAN 90% of the cases of congenital adrenal hyperplasia (CAH) are due to 21-hydroxylase (CYP21B) deficiency, whereas 5-8% arise from 11␤-hydroxylase (CYP11B1) deficiency (1, 2). Previously reported mutations on CYP11B1 are distributed over the entire coding region, but cluster in exons 2, 6, 7, and 8. In addition to missense mutations, nonsense and splice site mutations of the CYP11B1 gene were shown to occur (3-7).
M ORE THAN 90% of the cases of congenital adrenal hyperplasia (CAH) are due to 21-hydroxylase (CYP21B) deficiency, whereas 5-8% arise from 11␤-hydroxylase (CYP11B1) deficiency (1, 2) . Previously reported mutations on CYP11B1 are distributed over the entire coding region, but cluster in exons 2, 6, 7, and 8. In addition to missense mutations, nonsense and splice site mutations of the CYP11B1 gene were shown to occur (3) (4) (5) (6) (7) .
11␤-Hydroxylase (CYP11B1) is expressed in the zona fasciculata/reticularis (8) , is regulated by ACTH, and catalyzes the synthesis of cortisol from 11-deoxycortisol. Aldosterone synthase (CYP11B2) is expressed in the zona glomerulosa (9) , is mainly regulated by serum levels of angiotensin II (ANGII) as well as K ϩ , and catalyzes the synthesis of aldosterone from deoxycorticosterone via corticosterone and 18-hydroxycorticosterone (6, 10 -12) . In humans CYP11B1 and CYP11B2 are encoded by two genes, which lie tandemly arranged approximately 45 kb apart from each other on chromosome 8q24. The genes share 95% sequence homology within their nine exons and about 90% in their introns. The most significant difference between the two structural genes is a 442-bp insertion in intron 5 of CYP11B2 (10, (13) (14) (15) (16) . The presence of a chimeric CYP11B1/CYP11B2 gene has been shown as the cause of glucocorticoid-remediable aldosteronism (GRA) (14, (17) (18) (19) . The chimeric gene contains the 5Ј-regulatory sequence of CYP11B1 and the 3Ј-structural sequence of CYP11B2, so that expression of a protein with aldosterone synthase activity is under control of the CYP11B1 promotor and, thus, ACTH. This chimeric gene is located on the same chromatid as the normal genes for CYP11B1 and CYP11B2 (Fig. 1) . Published cross-over break points in GRA patients range from intron 2 to intron 4 (14, 18, 20) . The consequent high expression of aldosterone synthase results in primary aldosteronism, which can be inhibited by glucocorticoids. The opposite case of a chimeric gene containing the CYP11B2 promotor and the CYP11B1 structural gene has never been observed. In that case, one chromatid would only contain the CYP11B2/CYP11B1 chimera, with no normal genes for CYP11B1 and CYP11B2.
Here we describe the first case of a chimeric gene, where the CYP11B1 structural gene is under control of the aldosterone synthase promotor.
Subject and Methods Patient
The following data were obtained at the first examination of the 31-month-old Vietnamese male: Na ϩ , 141 mEq/liter; K ϩ , 3.4 mEq/liter, Cl Ϫ , 105 mEq/liter; estradiol, 37 pmol/liter; progesterone, 5.2 nmol/liter (elevated); and testosterone, 2.2 nmol/liter (elevated). The patient's blood pressure was 160 -170/80 -90 mm Hg, pulse was 110/min, weight was 15 kg, and height was 90 cm. Symptoms of sexual precocity occurred at the age of 24 months. The administration of prednisolone was started (5 mg/d) after diagnosing a hypertensive form of CAH. Within 6 wk of medical treatment blood pressure dropped to 110/70 mm Hg. The medication was changed to hydrocortisone (20 mg/d) when progesterone and testosterone levels remained elevated and concomitant hyperpigmentation of the skin occurred. At the age of 9 yr, the patient was 135 cm tall and weighed 29 kg, and his bone age was 13 yr, 9 months. Blood pressure was 100/60 mm Hg, progesterone was 5.43 nmol/liter, testosterone was 0.05 nmol/liter, and cortisol was 309 nmol/liter (medication was not ceased). The patient was in a low cortisol level (91 Abbreviations: ANGII, Angiotensin II; CAH, congenital adrenal hyperplasia; GRA, glucocorticoid-remediable aldosteronism. nmol/liter) situation (for an unknown reason) when another determination of the serum steroid concentrations was performed at the age of 9 yr. The concentrations of the precursors 11-deoxycortisol (49.8 nmol/ liter) and 11-deoxycorticosterone (10.33 nmol/liter, 17-deoxy pathway) were elevated. The corticosterone concentration was 5.8 nmol/liter, 17-hydroxyprogesterone was 3.6 nmol/liter, 17-hydroxypregnenolone was 2.73 nmol/liter, 21-desoxycortisol was 0.29 nmol/liter, dehydroepiandrosterone was 3.4 nmol/liter, and androstenedione was 5.27 nmol/liter.
PCR and sequencing
PCR A, B, and C (Fig. 2) were performed as described previously (3) (Table 1) were used for PCRs A ext., chimera, BϩC, and the entire gene, respectively. The incubation time at 72 C was 3 min for reactions A, B, and C; 4 min for reactions A ext., and BϩC; 5 min for PCR chimera; and 7 min for PCR of the entire gene. The cycle program was run for 30 cycles as described below in RT-PCR. The CombiPol PCR kit (InViTek) containing 3Ј to 5Ј proofreading activity was used for PCR chimera (Fig. 2) . We purified the amplified DNA by using QIAEX II gel extraction kit (QIAGEN). Big Dye terminator cycle sequencing kit (PE Applied Biosystems) and primers 1-16 (Table 1) were used to sequence both strands of the exons and adjoining intronic parts directly. Electrophoresis was performed on the ABI PRISM 377 DNA sequencer and analyzed with Sequencing Analysis software version 3.3.
Plasmids and cloning
Both the wild-type (from healthy control) and mutant PCR product spanning the complete coding part of CYP11B1 ( Fig. 2 ; PCR entire gene) were subcloned into pCR-XL-Topo (Invitrogen, San Diego, CA), excised with NotI/XbaI (restriction sites in primers 19 and 20, respectively; Table  1 ), and cloned into NotI and XbaI sites of pRc/CMV (Invitrogen). All exons and splice sites were sequenced to verify the integrity of the inserts.
Cell culture and transfection
COS-1 cells were cultured as previously described (21, 22) . One day before transfection cells were plated at a density of 4 ϫ 10 5 /6-cm dish. Four micrograms of each of the CYP11B1 mutant, wild-type, and control (pRc/CMV without insert) plasmids were transfected as previously described (22) . Twenty-four hours after transfection, total RNA was extracted from the cells using the RNAesy kit (QIAGEN, Chatsworth, CA).
RT-PCR
Two micrograms of total RNA and oligo(deoxythymidine) primer were used for RT, which was performed according to the Superscript II kit protocol (Life Technologies, Inc., Grand Island, NY). The PCR was performed with primers 19 and 20 (Table 1 ) and the CombiPol PCR kit (InViTek). The reaction conditions were denaturation at 95 C for 2 min, followed by 50 cycles at 94 C for 1 min, annealing at 64 C for 2 min, extension at 68 C for 2 min, and final extension for 5 min. The PCR products were purified from an agarose gel and ligated to pCR 2.1 (Invitrogen). Inserts were sequenced with primers 19, 20, 21, 22, 23, and 28 (Table 1) .
Southern blot
Five micrograms of genomic DNA each from the patient, a normal control, and a patient with GRA (previously described in Ref. 23) were digested with the restriction endonuclease BamHI for 16 h. The resulting fragments were separated on a 0.8% agarose gel and blotted onto a Nylon membrane (Hybond-Nϩ, Amersham Pharmacia Biotech, Arling-
Unequal crossing-over of aldosterone synthase (CYP11B2) and 11␤-hydroxylase (CYP11B1) genes. The genes are depicted as bars. The exons are colored light gray for CYP11B2 and black for CYP11B1. The figure outlines the genetic recombination that destroyed the maternal 11␤-hydroxylase allele of the examined patient. The high similarity of CYP11B1 and CYP11B2 enabled two chromatids to misalign for the meiotic cross-over, from which one chromatid emerged with only one (chimeric) CYP11B gene and the other with three (the reciprocal chimera between normal CYP11B2 and CYP11B1). In the investigated patient, the CYP11B2/CYP11B1 chimera of the former product, a chromosome 8 carrying only this chimeric CYP11B gene, was detected by PCR and subsequent sequencing ( Fig. 4B ; sequence data not shown) and by Southern blotting (Fig. 5 ). The reciprocal CYP11B1/CYP11B2 gene of the latter product was found by Lifton et al. (14, 17) to be the molecular genetic reason for GRA.
ton Heights, IL) with a vacuum blotting apparatus. The Gene Images random prime labeling module (Amersham Pharmacia Biotech, RPN3540) was used to generate a fluorescein-labeled probe from 100 ng product of PCR A (see Fig. 2 ). The blot was hybridized overnight and washed twice at 68 C with 0.1 ϫ SSC (standard saline citrate)/0.1% SDS for 30 min, and the hybrids were visualized with the Gene Images CDP-Star detection module (Amersham Pharmacia Biotech, RPN3510) on x-ray film. The image was scanned, and band intensities were determined with the program TINA 2.08e (Raytest Isotopenmessgeraete GmbH, Straubenhardt, Germany).
FIG. 2. PCR strategy.
The two different 11␤-hydroxylase alleles of the patient are depicted in the middle of the drawing. With the exception of PCR "entire gene," each performed PCR is depicted as two bars (one for each gene), of which filled bars above and below the genes mark fragments, which were successfully amplified for CYP11B1 and the chimeric gene, respectively. Empty bars represent failure of amplification within the corresponding PCR. Initially, the products of PCRs A, B, and C were screened for mutations. Heterozygous bases were found in exons 3 and 4 (see Fig. 3 and text) of PCR product B. As no other mutations were detected, PCR fragment A was extended to contain exon 3 (PCR A ext.). Sequencing revealed the amplification of only one allele (CYP11B1) within this PCR A ext. This led to the conclusion that the primer binding in the promoter of CYP11B1 abolished the amplification of the second (chimeric) allele. Therefore, this CYP11B1-specific primer was replaced by another one binding in the promoter region of the aldosterone synthase gene, as exons 3 and 4 of the mutated allele showed the sequence of this gene in the investigated fragment of PCR B (Fig. 3) . Furthermore, the reverse primer was exchanged for the one previously used in PCR B. The successful PCR chimera proved the existence of the chimeric gene in the patient as well as his mother and sister (Fig. 4B) . Fragments produced by PCRs A ext., BϩC, and the entire gene were used to search for the mutation within the apparently normal gene (CYP11B1) the patient inherited from his father (Fig. 6) . 1  115E1F  CAGTTCTCCCATGACGTG  2  3932E1R  GGGAATGGCAGTGCTGAGTG  3  663E2F  AGGGTGGACAGGAGACAC  4  3935E2R  CCTGCTCCCAGCTCTCAGCT  5  3933E3F  TGCAGGCCGATTCCCCTTGG  6  3934E3R  CTCCTGGCTGCCTCCCCACA  7  3936E4F  GTGGGGAGGCAGCCAGGAGG  8  180E4R  CTTCCCCATAGCACTGC  9  3938E5F  AGGAGGAGGACACTGAAGGATG  10  3939E5R  TGGCATCACCCTCTCTGGGTG  11  3940E6F  GGTGTCCCGGGGGCTGAGTC  12  664E6R  ATAGCCCAGATTCTGTCTG  13  117E7E8F  TAGGAAGGGTGCAGAGAG  14  3941E7R  TGCCGGAGCCCCTGATGTCT  15  4396E9F  TGTTCCCCCTTCAGCATAAT  16  85E9R  TGACTCAGGAAGCTGTGC  17  3931B2PromF  ACCAGACTTCTCCTTCATCTACCTT  18  3930B1PromF  CTTTTCCCCTGTCTACGCTCATGCA  19  4665eGF  GAGGGAGCGGCCGCATGGCACTCAGGGCAAAGGCAGA  20  4666eGR  AGAGTCTAGATTAGTTGATGGCTCTGAAGGTGAG  21  1274E2R  AGCAAGAACACGCCACA  22  184E2F  TGGAGCCCTGGGTGG  23  3156E7F  CTCAGACTTGGTGCTTCAGAACT  24  209F  CCCATGACGTGATCCCTCTCGAAGG  25  210R  AAACACAGGCCCTGACCCGTATCCC  26  211F  TCAGCACCTGTGGGCAGAAGCTACCA  27  212R  AGCGTCATCAGCAAGGGAAACACCG  28  213F  CGCCCTCAACAGTACACCAGCATCG  29 214R AAACCACAGCACCCTTGCATGGCCA
The primer name consists of a primer-specific number, followed by an E and the number of the exon that was sequenced with this primer (primers 1-16) or in which the primer was binding (primers [21] [22] [23] . The name ends with F or R for forward or reverse primers, respectively. Primers 17-20 and 24 -29 were used for PCRs. In primers 19 and 20 (eG stands for entire gene) the restriction sites for NotI and XbaI are underlined, respectively. Bold letters mark bases where CYP11B1 and CYP11B2 differ within their sequences at the binding site of the respective primer (13) .
Results
The patient, the son of a Vietnamese couple, showed typical symptoms of 11␤-hydroxylase deficiency when he was taken to a pediatrician at the age of 31 months because of abdominal pain. Besides signs of sexual precocity, a strikingly high blood pressure was observed (see Subject and Methods).
PCR amplification and DNA sequencing
A set of three overlapping PCRs (Fig. 2) was performed to amplify the complete structural gene of the 11␤-hydroxylase. Sequencing of the obtained products revealed heterozygosity at all positions in exon 3, intron 3, and exon 4, which are different in the highly similar 11␤-hydroxylase and aldosterone synthase genes (Fig. 1) . In all cases the CYP11B1 sequence was replaced by the corresponding sequence of CYP11B2, which gave rise to the three amino acid exchanges, E147D, N152K (Fig. 3) , and T248I. These changes were very unlikely to destroy the 11␤-hydroxylase activity, as the corresponding mutants investigated in our laboratory (data not shown) and by others (T248I) (24) had been found to exhibit unchanged or increased 11␤-hydroxylase activity.
PCR and sequence of the CYP11B2/CYP11B1 chimera
To investigate whether a gene conversion, an unequal cross-over, or a PCR artifact was the reason for the observed mutations, PCR A was performed with a different 3Ј-end primer ( Fig. 2 ; PCR A ext.) which bound downstream of exon 3 in CYP11B1 as well as in CYP11B2. The sequence of the PCR product showed a loss of the heterozygous positions. This indicated that the forward primer binding in the CYP11B1 promoter, which is only 48% similar to that of CYP11B2 (10) , discriminated between an apparently normal CYP11B1 allele and the mutated allele, which was not amplified in this reaction. For amplification of the mutant allele, a long range PCR ( Fig. 2 ; PCR chimera), using a forward primer binding in the CYP11B2 promoter and a reverse primer binding specifically a sequence in exon 6 of CYP11B1, was performed. The successful PCR (Fig. 4) supported the theory that an unequal cross-over created the chimeric allele. The PCR product ( Fig. 2; PCR chimera) showed the sequence of CYP11B2 up to intron 4, where it switched to that of CYP11B1.
It is noteworthy that the sequence of intron 2 of the chimeric gene was almost identical to the normal sequence of the corresponding intron in CYP11B1. This is a common polymorphism in the aldosterone synthase gene (CYP11B2) which was described previously by White and Slutsker (25) .   FIG. 3 . Heterozygosity in exon 3. Sequencing of the PCR product B (Fig. 2 ) with primer 5 (Table 1) revealed four heterozygous positions in exon 3, which are shown in the electropherogram and the sequence of the upper panel. The mutations would have caused two amino acid exchanges and in two cases the utilization of a different codon for the same amino acid residue. These modifications are depicted above the upper sequence. In all four cases the nucleotides were exchanged for those normally found in the sequence of the aldosterone synthase gene (CYP11B2) at these positions. The corresponding homozygous CYP11B2 sequence, depicted in the middle panel, was obtained when the product of PCR chimera (Fig. 2) was sequenced with the same primer. PCR chimera was found to exclusively amplify the maternal allele (Fig. 4B ). The lower panel shows the matching sequence of the paternal allele that was amplified in PCR A ext. (Fig. 2) . This sequence corresponds to the normal CYP11B1 sequence (13).
FIG. 4. Pedigree (A) and detection of the chimeric gene (B)
. A, The pedigree shows all investigated family members. The father (I1) and mother (I2) are heterozygotes for the intronic mutation (I) and the chimeric gene (C), respectively. The son (II1, index case) inherited both of these alleles from his parents. The sister (II2) and brother (II3) are heterozygous carriers of the chimeric gene and the gene with intronic mutation, respectively (sequence data for II3 not shown). B, Analysis of the DNA using PCR chimera (Fig. 2) , followed by electrophoresis on an 0.8% agarose gel. The DNA fragment of 4.1 kb in lanes II1, I2, and II2 demonstrates the presence of the CYP11B2/ CYP11B1 chimera in the patient, his mother, and his sister, respectively. The band running at 4.55 kb in lanes II1, I1, II2, and II3 (very faint in I2) represents the amplification of the corresponding CYP11B2 gene fragment, which has an insertion of 442 bases in intron 5 (Fig. 1) . This amplification was caused by using a PCR kit containing polymerase with 3Ј to 5Ј exonuclease proofreading activity, which made the reverse CYP11B1-specific primer fit to the respective sequence in CYP11B2 (only 3-base difference). This primer repair provided an internal control reaction, which confirmed that missing amplification of the 4.1-kb product was not due to bad conditions in the PCR. The father (I1) and brother (II3) were not found to be carriers of the chimeric gene, as their PCRs amplified only the longer control fragment. In lane M, the DNA size marker (-DNA-digested EcoRI/ HindIII) was loaded onto the gel. Numbers indicate the lengths of the marker fragments in base pairs.
Due to this polymorphism, both genes, the chimera and CYP11B1, were amplified in PCR B (Fig. 2) .
The mother and sister of the patient were found to be carriers of the chimeric gene when all available family members were tested by PCR (Fig. 4, A and B) .
Southern blot
To demonstrate that the proposed unequal cross-over had created the observed chimeric gene, a Southern blot was performed (Fig. 5) . The digestion of genomic DNA with BamHI would yield a characteristic band at 6.5 kb when hybridized with an exon 1-intron 2 probe. Furthermore, quantitation of the respective fragments should show a 1:1:1 ratio of CYP11B2, the chimera, and CYP11B1.
We analyzed the DNA samples from the patient, a normal control without any aberrations of adrenal steroid metabolism, and a patient with GRA (see Ref. 23 for a detailed description of the patient). The latter was included as a control because the BamHI digestion of genomic DNA from a person with GRA generates a similar anomalous fragment of 6.3 kb on the Southern blot. However, the most significant difference between our 11␤-hydroxylase-deficient patient and a GRA patient is the number of gene copies on the affected chromosome (Fig. 1) . It was shown that this chromosome contains one copy each of CYP11B2, the chimera accounting for GRA, and CYP11B1 in a GRA patient (14) . In the investigated patient with 11␤-hydroxylase deficiency, it is supposed to contain just the CYP11B2/CYP11B1 chimera.
Hybridization of the exon 1-intron 2 probe to the blot detected, besides the normal bands for CYP11B1 (8.5 kb) and CYB11B2 (4.4 kb), the predicted 6.5-kb fragment in the DNA of our patient and the 6.3-kb fragment in the DNA of the GRA patient. Quantitation (not shown) confirmed a ratio of CYP11B1:chimera:CYP11B2 genes of 1:1:1 for the 11␤-hydroxylase-deficient patient and 2:1:2 for the patient with GRA. This indicates a single additional gene (CYP11B2/ CYP11B1 chimera) and the deletion of one copy each of CYP11B1 and CYP11B2 within the diploid genome of our patient.
Polymorphisms and minigene expression of CYP11B1
The chimera, however, explained the disruption of one allele. As 11␤-hydroxylase deficiency is inherited as an autosomal recessive trait, a mutation was hidden in the allele inherited from the father.
Besides the five polymorphisms R43Q, D82D (GAT3 GAC), L362L (CTG3 CTC), A386V, and C494F no other differences were found within the exons and the splice sites (data not shown) when the sequence was compared with that reported by Mornet et al. (13) . Therefore, an intron mutation disrupting right splicing or a cumulative effect of the polymorphisms was considered to diminish the enzyme's activity.
A minigene expression of the complete CYP11B1 structural gene (5.5 kb) was performed in COS-1 cells to detect any mutations causing wrong splicing of the primary transcript and to obtain the corresponding cDNA for subsequent activity tests.
RT-PCR with the isolated total RNA amplified a fragment of the expected size (ϳ1550 bp), which was ligated to a cloning vector. When the identity of the insert was checked, an intronic insertion consisting of the first 14 bases of intron 3 was observed between exon 3 and exon 4 in all three investigated cDNA clones. A G3 T transversion at position 16 of intron 3 (IVS3ϩ16G3 T) was found when sequence data of the exon 3/intron 3 boundary of the patient and the father were reexamined (Fig. 6) . The mutation created the typical GT consensus of a donor splice site.
Expression of the control minigene construct, derived from a patient without 11␤-hydroxylase deficiency, resulted FIG. 5. Southern blotting. Five micrograms of genomic DNA each from the patient, a control, and a patient with GRA were digested with the restriction endonuclease BamHI, fractionated via agarose gel electrophoresis, transferred to a nylon membrane, and hybridized with the exon 1-intron 2 CYP11B1 probe. The picture in the middle shows the result of the hybridization. Next to the blot, the maps of the detected genes are shown. Each map indicates the BamHI sites of the respective gene and the size of its BamHI fragment. The patient with 11␤-hydroxylase deficiency has the 6.5-kb BamHI fragment that is characteristic for the deletion chimera. The DNA of the patient with GRA shows a very similar fragment of 6.3 kb, which arises from the reciprocal chimeric gene (see Fig. 1 ). None of these fragments is found in the normal control. Quantitation of the gene copies on the basis of the band intensities resulted in the ratios depicted in the small table under the blot. A ratio of 1:1:1 of CYP11B1:chimera:CYP11B2 confirmed the deletion of one copy each of CYP11B1 and CYP11B2 and the addition of the CYP11B2/ CYP11B1 chimera in the diploid genome of the patient. In the GRA patient a 2:1:2 ratio was found, indicative of a single additional gene (the GRA chimera) per diploid genome. in all cases, as shown in the lowest panel of Fig. 6 , in normal splicing of exons 3 and 4. Calculation of the scores (or consensus values) according to Senapathy et al. (26, 27) showed the new site to have a higher score (85.1) than the normal donor splice site of intron 3 (80.2), which is still present and unmutated. Krawczak et al. (28) calculated a mean consensus value of 83 when they analyzed 406 donor splice sites from a random selection of 29 human genes. Values below 70 were found in less than 15% of the donor splice sites, although the score can theoretically range from 0 -100. As a splice site with a higher score is not always associated with the exclusive recognition by the spliceosome (29) , another RT-PCR was performed to compare the frequencies of the splice site utilization in COS-1 cells. Thirty-three of 33 investigated clones contained the 14-bp insert, whereas 4 of 4 clones lacking the intronic mutation were found to be normally spliced (Fig. 6) .
Discussion
Molecular genetic analysis of a male Vietnamese patient with CAH revealed two new mutations of the 11␤-hydroxylase gene. One allele had been formed by an unequal crossing-over, which created a chimeric fusion gene composed of the promoter and exon 1 to exon 4 of CYP11B2 and intron 4 to exon 9 of CYP11B1. The second allele comprises a mutation in intron 3, which leads to a wrong splicing of the primary mRNA transcript.
Former studies from our laboratory showed that the enzyme encoded by the chimeric gene is most likely an active 11␤-hydroxylase (21) . The amount of the protein formed under control of the aldosterone synthase promoter, however, will be considerably less than the amount formed under the original 11␤-hydroxylase promotor, as human aldosterone synthase is expressed in the adrenal cortex at a level much lower than 11␤-hydroxylase (30) . The expression is probably driven by ANGII and K ϩ instead of ACTH and is limited to the adrenal zona glomerulosa, which lacks the expression of 17␣-hydroxylase, an enzyme acting further upstream in the biosynthetic pathway of cortisol. As adrenal circulation is mainly centripetal (from the capsule/zona glomerulosa to the medulla) (31), only minimal amounts of the 11␤-hydroxylase substrate 11-deoxycortisol produced by the zona fasciculata would be expected to reach zona glomerulosa cells expressing the chimeric 11␤-hydroxylase. Thus, the changed spatial expression within the adrenal cortex, the changed level of expression, and the switch of the main expression stimulus from ACTH to ANGII and K ϩ result in a reduction of the cortisol synthesis being low enough to cause CAH.
The discovered chimeric gene showed all of the features proposed by Lifton et al. (14) for a reciprocal product of the unequal cross-over between CYP11B1 and CYP11B2, when he published his findings about the genetic reason for GRA, a dominant inherited form of hypertension.
Our clinical and genetic data showed that the discovered deletion chimera and the intronic mutation behaved as null alleles. Heterozygotes were phenotypically normal. Compound heterozygotes (as in our case) for the chimeric allele in combination with an 11␤-hydroxylase deficiency allele show the phenotype of 11␤-hydroxylase deficiency (see Subject and Methods).
The existence of the deletion chimera was demonstrated by Southern blot. The additional band at 6.5 kb and quantitation of the gene copies ruled out the possibility that a gene conversion or a PCR artifact generated the anomalous PCR fragments that had been observed at the first screening for mutations.
The intronic mutation within the second 11␤-hydroxylase allele of the patient was revealed by a minigene expression of the structural gene of CYP11B1 in COS-1 cells. All investigated cDNA clones contained a 14-bp insert between exons Addition of the two lower sequences results in the heterozygous, upper sequence of the patient. The sequence data were obtained in the same reactions as described in Fig. 3 . The breakpoint, where the exon extends into the intron, is marked in the first electropherogram directly underneath the sequences. As there were no mutations found within the exons and splice sites of the paternal allele, a cumulative effect of the five observed polymorphisms (see text) was considered to destroy the activity of the enzyme. A minigene expression of the structural gene of CYP11B1 was performed to obtain the corresponding cDNA for the determination of the 11␤-hydroxylase activity. The RT-PCR (see Subject and Methods) amplified a product of the desired length (data not shown), which was ligated to a cloning vector. An insertion consisting of the first 14 bases of intron 3 was found between exon 3 and exon 4 in all resulting cDNA clones. The insertion is marked in the electropherogram of the panel "mutated cDNA." The sequence of the insert is shaded. A G3 T transversion of the 16th base of intron 3 (IVS3ϩ16G3 T) created a wrong donor splice site, the GT consensus of which is shaded in the sequence of the paternal allele and marked in the corresponding electropherogram.
3 and 4. This insert causes a shift of the reading frame, and the result of this is a premature translation stop in exon 4 (codon 226 of the mutated mRNA). The 11␤-hydroxylase, a cytochrome P450 enzyme, uses heme as a prosthetic group for the hydroxylation of its substrates. The heme-binding domain of the human 11␤-hydroxylase is thought to be located between codons 443 and 463 (32) . The loss of this functional domain will abolish the activity of our truncated mutant completely. Furthermore, earlier in vitro studies showed that the mere deletion of the eight C-terminal residues 496 -503 rendered the enzyme inactive (22) .
Our experiments showed that COS-1 cells can be used to obtain complete cDNAs from genomic DNA of steroid hydroxylases. To our knowledge this is the second publication after that by Higashi et al. (33) that describes the in vitro expression of an adrenal steroid hydroxylase gene for the detection of intronic mutations. The method, originally published in the late 1970s (34, 35) , could be a helpful tool for studying frequent polymorphisms and mutations in short genes of the entire P450 superfamily, which includes the adrenal steroid hydroxylases, the exons of which are mostly arranged within a relatively short DNA section [CYP21B, 2.7 kb (36); 17␣-hydroxylase (CYP17), 6.4 kb (37)].
To date, all defects in the CYP11B1 gene have been found to be due to nonsense, missense, or splice site mutations (5) . That 11␤-hydroxylase deficiency can result from unequal crossing-over raises the possibility that such mutations may be more common than is presently recognized. The reciprocal GRA chimera, which emerges from the same recombination event and consists of the 11␤-hydroxylase promoter and the aldosterone synthase-coding region, is being detected with increasing frequency (38, 39) . Therefore, it is advisable that patients with CAH in whom no mutations are found within the coding regions of the 21-hydroxylase and 11␤-hydroxylase (40, 41) should be tested for the deletion chimera consisting of aldosterone synthase promoter and 11␤-hydroxylase-coding region. The same applies for aldosterone synthase deficiency. The chimera would definitely behave as a complete CYP11B2 null allele as long as the cross-over point is upstream of exon 5, which codes together with exon 6 for the amino acids, which confer aldosterone synthase activity to the enzyme (21, 22, 24, 42) . The finding of the cross-over allele, the performed long range PCRs for the detection of biallelic amplification, and the described minigene expression method will hopefully unveil secrets about the "phenotype does not match genotype" cases and lead to deeper insight into the molecular genetic basis of adrenal steroid hydroxylase deficiencies.
